MedTrace Logo

Investigation of Asprosin a Novel Adipokine in Periodontitis

NCT05449821 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2023-02-01

No results posted yet for this study

Summary

Asprosin, a recently discovered glucogenic adipokine, is mainly synthesized by white adipose tissue and released during fasting. Appetite, glucose metabolism, insulin resistance, cell apoptosis, etc. asprosin is associated with diseases such as diabetes, obesity, polycystic ovary syndrome, and cardiovascular diseases. Periodontal tissue may act as a source of endocrine-like inflammatory mediators (such as TNF-α, IL-6 and IL-1) that are important in periodontal inflammation and can affect glucose and lipid metabolism. Production of TNF-α and IL-6 in adipose tissues strengthens the relationship between obesity, T2DM and periodontitis.we postulated that asprosin may be candidate for explaining the triangular relationship among obesity, T2DM, and periodontal disease.

Conditions

Interventions

DIAGNOSTIC_TEST

Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis

Serum and saliva samples will be collected from both groups for biochemical analysis.

Sponsors & Collaborators

  • Ataturk University

    lead OTHER

Principal Investigators

  • Didem Özkal Eminoğlu, Asist. Prof. · Atatürk University, Faculty of Dentistry

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2022-11-01
Completion
2022-12-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05449821 on ClinicalTrials.gov